Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from BTIG Research

BTIG Research restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Friday morning, Marketbeat Ratings reports. They currently have a $10.00 price objective on the stock.

A number of other analysts have also issued reports on HUMA. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Humacyte presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Humacyte Stock Performance

Shares of HUMA opened at $5.03 on Friday. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97. The company’s 50 day simple moving average is $5.78 and its 200 day simple moving average is $5.93. The company has a market capitalization of $598.99 million, a price-to-earnings ratio of -5.03 and a beta of 1.45. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, sell-side analysts predict that Humacyte will post -1.09 EPS for the current year.

Insider Transactions at Humacyte

In related news, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the transaction, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the sale, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,084,153 shares of company stock worth $6,869,996. 23.10% of the stock is currently owned by company insiders.

Institutional Trading of Humacyte

A number of hedge funds have recently made changes to their positions in HUMA. nVerses Capital LLC acquired a new stake in Humacyte during the 2nd quarter valued at $28,000. Hartline Investment Corp acquired a new stake in shares of Humacyte during the first quarter valued at about $70,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte during the second quarter valued at about $83,000. Profund Advisors LLC purchased a new stake in shares of Humacyte during the second quarter worth about $97,000. Finally, XTX Topco Ltd acquired a new position in shares of Humacyte in the second quarter worth about $110,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.